Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/20/2025

COPD Management with Trelegy

Mechanism of Action

  • The combination of fluticasone furoate, umeclidinium, and vilanterol in Trelegy improves lung function, reduces symptoms, and decreases exacerbation rates more effectively than single or dual therapies, by combining three complementary mechanisms of action in a single inhaler: an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA) 1
  • Umeclidinium (LAMA) acts as an anticholinergic agent that blocks muscarinic receptors in airway smooth muscle, prevents acetylcholine-induced bronchoconstriction, reduces airway smooth muscle tone, and has a greater effect on exacerbation reduction compared to LABAs 1
  • Vilanterol (LABA) stimulates β2-adrenergic receptors in airway smooth muscle, promotes smooth muscle relaxation, and improves airflow and lung emptying during tidal breathing 2
  • Fluticasone furoate (ICS) acts at multiple points within the inflammatory cascade, produces a small increase in post-bronchodilator FEV1, reduces bronchial reactivity in stable COPD, and is particularly beneficial in patients with FEV1 <50% predicted, reducing exacerbations and slowing health status deterioration 1, 2

Efficacy

  • The combination of all three medications produces greater improvements in spirometry than single agents or dual therapy 2
  • Airway smooth muscle relaxation is achieved through the complementary effects of LAMA and LABA components, producing greater bronchodilation than either agent alone 1
  • The combination therapy produces larger changes in lung volumes, which significantly contribute to reduced breathlessness 2
  • The ICS component addresses the inflammatory component of COPD, providing superior exacerbation prevention when combined with bronchodilators 1

Patient Selection

  • Patients with moderate to very severe COPD (FEV1 <50% predicted) may benefit from Trelegy, particularly those with a history of exacerbations despite dual therapy, or symptomatic patients despite being on monotherapy or dual therapy 1

Safety

  • The ICS component increases the risk of pneumonia, especially in current smokers, patients aged ≥55 years, those with prior exacerbations or pneumonia, and patients with BMI <25 kg/m² 1
  • Other potential adverse effects include oral candidiasis, hoarse voice, and skin bruising 1